Latest filings (excl ownership)
8-K
Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus
4 Apr 24
S-8
Registration of securities for employees
11 Mar 24
10-K
2023 FY
Annual report
11 Mar 24
8-K
Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
11 Mar 24
8-K
Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024
8 Jan 24
8-K
Departure of Directors or Certain Officers
22 Dec 23
8-K
Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024
12 Dec 23
10-Q
2023 Q3
Quarterly report
7 Nov 23
8-K
Caribou Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update
7 Nov 23
8-K
Regulation FD Disclosure
18 Oct 23
8-K
Termination of a Material Definitive Agreement
26 Sep 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
8-K
Caribou Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update
8 Aug 23
8-K
Caribou Biosciences Announces Proposed Public Offering of Common Stock
14 Jul 23
424B5
Prospectus supplement for primary offering
14 Jul 23
8-K/A
Other Events
14 Jul 23
424B5
Prospectus supplement for primary offering
13 Jul 23
8-K
Caribou Biosciences Reports Positive Clinical Data from Dose Escalation of CB-010 ANTLER Phase 1 Trial in r/r B-NHL
13 Jul 23
8-K
Other Events
13 Jul 23
8-K
Caribou Biosciences Announces $25 Million Equity Investment from Pfizer
6 Jul 23
8-K
Submission of Matters to a Vote of Security Holders
16 Jun 23
10-Q
2023 Q1
Quarterly report
9 May 23
8-K
Caribou Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update
9 May 23
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
8-K
Regulation FD Disclosure
4 Apr 23
8-K
Regulation FD Disclosure
29 Mar 23
8-K
Regulation FD Disclosure
29 Mar 23
8-K
Other Events
24 Mar 23
S-8
Registration of securities for employees
9 Mar 23
10-K
2022 FY
Annual report
9 Mar 23
8-K
Caribou Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
9 Mar 23
8-K
Departure of Directors or Certain Officers
16 Dec 22
8-K
Caribou Biosciences Reports CB-010 ANTLER Phase 1 Trial Progress
12 Dec 22
8-K
Regulation FD Disclosure
29 Nov 22
8-K
Regulation FD Disclosure
21 Nov 22
10-Q
2022 Q3
Quarterly report
8 Nov 22
Latest ownership filings
SC 13G
Point72 Asset Management, L.P.
23 Feb 24
4
Jason O'Byrne
22 Feb 24
4
BARBARA G MCCLUNG
22 Feb 24
4
Ruhi Ahmad Khan
22 Feb 24
4
Rachel E. Haurwitz
22 Feb 24
4
Steven Kanner
22 Feb 24
4
Ran Zheng
22 Feb 24
4
Nancy Whiting
22 Feb 24
4
Natalie Sacks
22 Feb 24
4
Dara Richardson-Heron
22 Feb 24
4
DAVID LEE JOHNSON
22 Feb 24
4
ANDREW GUGGENHIME
22 Feb 24
4
Scott Braunstein
22 Feb 24
SC 13G/A
PFM Health Sciences, LP
14 Feb 24
SC 13G/A
Point72 Asset Management, L.P.
14 Feb 24
4
Steven Kanner
8 Feb 24
SC 13G/A
BlackRock Inc.
25 Jan 24
SC 13G/A
STATE STREET CORP
25 Jan 24
3/A
Timothy P Kelly
10 Jan 24
4
Timothy P Kelly
9 Jan 24
3
Timothy P Kelly
9 Jan 24
SC 13G
Avidity Partners Management LP
8 Jan 24
SC 13G
Point72 Asset Management, L.P.
20 Jul 23
SC 13G
PFIZER INC
10 Jul 23
4
Rachel E. Haurwitz
9 Jun 23
4
Rachel E. Haurwitz
22 Mar 23
4
Rachel E. Haurwitz
23 Feb 23
4
Steven Kanner
23 Feb 23
4
Dara Richardson-Heron
23 Feb 23
4
Ruhi Ahmad Khan
23 Feb 23
4
Natalie Sacks
23 Feb 23
4
Scott Braunstein
23 Feb 23
4
ANDREW GUGGENHIME
23 Feb 23
4
BARBARA G MCCLUNG
23 Feb 23
4
Syed Ali-aamir Rizvi
23 Feb 23
4
Ran Zheng
23 Feb 23
4
Nancy Whiting
23 Feb 23
4
Jason O'Byrne
23 Feb 23
4
DAVID LEE JOHNSON
23 Feb 23
SC 13G/A
PFM Health Sciences, LP
14 Feb 23